We have located links that may give you full text access.
Risk Factors of de novo Hepatitis B Virus Infection in Pediatric Hepatitis B Core Antibody Positive Liver Graft Recipients under Prophylactic Therapy.
Journal of Gastroenterology and Hepatology 2019 October 15
AIMS: To investigate the risk factors of de novo hepatitis B virus (HBV) infection in pediatric liver transplantation recipients receiving hepatitis B core antibody (HBcAb) positive grafts and to evaluate the efficacy of our prophylactic strategies.
METHODS: 139 pediatric recipients receiving HBcAb positive grafts operated from September 2016 to September 2018 were retrospectively enrolled, all the patients received prophylactic treatment to prevent de novo HBV infection. Donor and recipient features, operative information along with graft and recipient outcomes were compared between recipients with or without de novo HBV infection. Univariate and multivariate analysis were applied to identify the risk factors of de novo HBV infection.
RESULTS: The mean follow-up time was 23.5 ± 15.7 months, the overall incidence of de novo HBV infection was 3.6%. Recipients with de novo HBV infection showed equal graft and recipient outcome compared to the recipients without de novo HBV infection during the follow-up time. Recipient pre-operative hepatitis B surface antibody (HBsAb) titer < 1000 IU/L (OR = 9.652, p = 0.024), Graft HBV DNA > 1000 copies (OR = 9.050, p = 0.032) and intra-operative fresh frozen plasma (FFP) transfusion > 400 ml (OR = 10.462, p = 0.023) were identified as independent risk factors for de novo HBV infection.
CONCLUSIONS: HBcAb positive grafts can safely be used in pediatric liver transplantation under rational prophylactic therapy.
METHODS: 139 pediatric recipients receiving HBcAb positive grafts operated from September 2016 to September 2018 were retrospectively enrolled, all the patients received prophylactic treatment to prevent de novo HBV infection. Donor and recipient features, operative information along with graft and recipient outcomes were compared between recipients with or without de novo HBV infection. Univariate and multivariate analysis were applied to identify the risk factors of de novo HBV infection.
RESULTS: The mean follow-up time was 23.5 ± 15.7 months, the overall incidence of de novo HBV infection was 3.6%. Recipients with de novo HBV infection showed equal graft and recipient outcome compared to the recipients without de novo HBV infection during the follow-up time. Recipient pre-operative hepatitis B surface antibody (HBsAb) titer < 1000 IU/L (OR = 9.652, p = 0.024), Graft HBV DNA > 1000 copies (OR = 9.050, p = 0.032) and intra-operative fresh frozen plasma (FFP) transfusion > 400 ml (OR = 10.462, p = 0.023) were identified as independent risk factors for de novo HBV infection.
CONCLUSIONS: HBcAb positive grafts can safely be used in pediatric liver transplantation under rational prophylactic therapy.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app